Lately, a selective MEK1/2 inhibitor, MEK‐162, demonstrated its potential for treating CD through the suppression of ERK1/2‐mediated phosphorylation activation of TR4,21 which provided an example to treat CD by targeting TR4. The gene discussed is MAPK3; the disease is Cowden disease.